Zentalis Pharmaceuticals (ZNTL) Liabilities and Shareholders Equity (2019 - 2026)

Zentalis Pharmaceuticals has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $253.1 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 34.1% year-over-year to $253.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (down 30.5% YoY), and the FY2025 full-year result was $289.0 million, down 32.85% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $253.1 million, down from $289.0 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $621.4 million in Q2 2023, with the low at $253.1 million in Q1 2026.
• Average Liabilities and Shareholders Equity over 5 years is $460.3 million, with a median of $489.3 million recorded in 2023.
• Year-over-year, Liabilities and Shareholders Equity jumped 99.98% in 2022 and plunged 34.1% in 2026.
• Tracing ZNTL's Liabilities and Shareholders Equity over 5 years: stood at $539.3 million in 2022, then rose by 2.3% to $551.7 million in 2023, then slipped by 22.0% to $430.3 million in 2024, then tumbled by 32.85% to $289.0 million in 2025, then slipped by 12.42% to $253.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $253.1 million (Q1 2026), $289.0 million (Q4 2025), and $327.2 million (Q3 2025), per Business Quant data.

Peer Comparison